RZLT
Rezolute Inc
NASDAQ: RZLT · HEALTHCARE · BIOTECHNOLOGY
$4.22
+2.68% today
Updated 2026-10-28
Market cap
$369.48M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.75
Dividend yield
—
52W range
$1 – $11
Volume
1.6M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.0
Quality
B3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-2.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →271 stocks currently score above 75
Price targets
Analyst target
$9.80
+132.23%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy8 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -2.41 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-13.15M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-51.79M | $-68.46M | $-74.41M | $-77.59M | $-20.49M |
| EPS | — | — | — | — | $-0.75 |
| Free cash flow | $-44.63M | $-57.37M | $-69.08M | $-64.64M | $-13.15M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-10-21 | EVANS, DARON | G | 16,000 | — |
| 2026-10-21 | EVANS, DARON | G | 4,000 | — |
| 2026-09-02 | KARNAWAT, SUNIL RATILAL | Sale | 2,267 | $4.50 |
Peer comparison
Smart narrative
Rezolute Inc trades at $4.22. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -2.41, it sits in the distress.
Frequently asked questions
What is Rezolute Inc's stock price?
Rezolute Inc (RZLT) trades at $4.22.
Is Rezolute Inc overvalued?
Rezolute Inc carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Rezolute Inc (RZLT)?
The 12-month analyst consensus target is $9.80, about 132.2% above the current $4.22. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Rezolute Inc's Altman Z-Score is -2.41, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-77.06%
Beta0.54
50D MA$4.30
200D MA$3.86
Shares out0.10B
Float0.06B
Short ratio—
Avg volume1.6M
Performance
1 week+7.68%
1 month-2.16%
3 months-22.75%
YTD+63.35%
1 year-58.05%
3 years—
5 years—